RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
RBC Capital analyst Luca Issi maintains $Editas Medicine(EDIT.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 22.6% and a
Editas Medicine (EDIT) Receives a Hold From RBC Capital
Jones Trading Initiates Coverage On Editas Medicine With Buy Rating, Announces Price Target of $13
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
JonesTrading analyst Soumit Roy initiates coverage on $Editas Medicine(EDIT.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 23.5%
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine to Participate in Upcoming Investor Conferences